Nektar Net Income Applicable To Common Shares from 2010 to 2026

NKTR Stock  USD 71.33  0.33  0.46%   
Nektar Therapeutics Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to grow to about -314.8 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2000-03-31
Previous Quarter
-137 M
Current Value
-51.1 M
Quarterly Volatility
114.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Interest Expense of 24.1 M or Total Revenue of 160.5 M, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0 or PTB Ratio of 2.69. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Nektar Stock
Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.
Evaluating Nektar Therapeutics's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Nektar Therapeutics's fundamental strength.

Latest Nektar Therapeutics' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Nektar Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Nektar Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Nektar Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(203,855,617)
Geometric Mean227,620,051
Coefficient Of Variation(132.85)
Mean Deviation179,868,300
Median(171,855,000)
Standard Deviation270,827,422
Sample Variance73347.5T
Range1.2B
R-Value(0.39)
Mean Square Error66297.1T
R-Squared0.15
Significance0.12
Slope(20,951,838)
Total Sum of Squares1173559.9T

Nektar Net Income Applicable To Common Shares History

2026-314.8 M
2025-331.4 M
2022-368.2 M
2021-523.8 M
2020-444.4 M
2019-440.7 M
2018681.3 M

About Nektar Therapeutics Financial Statements

Nektar Therapeutics shareholders use historical fundamental indicators, such as Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-331.4 M-314.8 M

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Nektar Stock

  0.67KG Kestrel Group Symbol ChangePairCorr

Moving against Nektar Stock

  0.65C43 Cosmo PharmaceuticalsPairCorr
  0.63LDZU ASPEN PHARUNADR 1PairCorr
  0.63TEV Teva PharmaceuticalPairCorr
  0.62MRK Merck KGaAPairCorr
  0.59R9U2 Green Thumb IndustriesPairCorr
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.